Access & pricing.
Guide access and pricing decisions with evidence and insight.
How we help.
We help healthcare decision-makers assess the value and effectiveness of innovative therapies by translating scientific evidence into clear, actionable insights. By combining deep payer expertise, rigorous clinical analysis, and a global understanding of access requirements, we enable thoughtful decisions to ensure patients, clinicians, and health systems can benefit from meaningful advancements. We support access & pricing teams to:
- Evaluate therapeutic value by translating clinical evidence, unmet needs, and real-world insights into clear narratives that support payer, clinician, and policy decision-making.
- Inform pricing, reimbursement, and access decisions through HTA-aligned evidence, economic modeling, and global payer insight that reflect the realities of diverse healthcare systems.
- Strengthen ongoing access and outcomes by integrating HEOR perspectives, real-world data, and analytics to guide reimbursement, optimize value communication, and support equitable patient access.
Some of our experts.
Meet the experts behind the solutions delivering meaningful impact for our clients.
Eric Auger, Partner, Value, Pricing & Access Practice Lead
Eric leads Putnam’s global Value, Pricing & Access practice of 250+ professionals across 10 offices. With 27+ years at Putnam, he specializes in market access strategy and helps clients navigate payer, healthcare system, and competitive environments.
Joanne Evason, Partner, Market Access Strategy
Joanne leads Putnam’s European Value, Pricing & Access practice. With 18 years’ experience, she advises biopharma from early asset planning through launch, helping clients navigate complex payer and healthcare systems to enable optimal patient access.
Scott Briggs, Partner
Scott advises clients across Value, Pricing & Access, Commercial Strategy, and Business Analytics. He has extensive global experience across vaccines, infectious disease, oncology, rare diseases, orthopedics, immunology, renal disorders, and neurology.
Alex Busch, Partner
Alex advises clients at the intersection of transformative pharmacology, commercial strategy, and Value, Pricing & Access. He supports global and emerging biotech companies on pre-launch and in-line strategy across major pharma markets.
Clement Francois, Partner, HTA & Market Access Operations
Clement leads the HTA and Market Access Operations team, advising biopharma from early asset planning through launch. He brings deep HEOR, HTA, and market access experience, including 15 years leading global HEOR teams in industry.
Simon Pannett, Partner, HTA & Market Access
Simon is a seasoned market access leader advising clients from asset strategy through peak sales. He has delivered numerous HTAs, negotiations, and pricing strategies across hematology, oncology, ophthalmology, neurology, and rare diseases.
Insights & latest.
Access the most up-to-date health and life sciences insights and resources.
-
Thought LeadershipRead more
Value of Equity in HTA: Current Guidelines and What to Expect
Equity in HTA is evolving. Explore current guidelines, future trends, and how Putnam advances equity methods in health assessments.
-
Thought LeadershipRead more
Why Real-World External Control Arms Are Gaining Ground in Health Technology Assessment
Discover how real-world external control arms (RW-ECAs) provide robust comparative evidence for HTA submissions when RCTs are impractical or unethical
-
Thought LeadershipRead more
Unlocking Patient Insights in HEOR Through Netnography: A Scalable Qualitative Research Method
In pharma commercialization, AI and analogs set the stage, but human insight drives strategies that break precedent and win markets
-
Thought LeadershipRead more
Unpacking MFN 2.0
Yesterday, the Trump Administration issued a much-anticipated Executive Order to introduce international reference pricing to the US market.
Connect.
Let’s discuss how we can help you.